Tumor cells often over-express one or several immune checkpoint ligands, which bind to immune receptors present on the surface of T cells resulting in the blocking of T cell activation. Monoclonal therapeutic antibodies that block checkpoint inhibitors PD-1, PD-L1 or CTLA4 have shown remarkable efficacy in some types of cancer. Other checkpoint regulators are now under intense scrutiny. This eBook investigate some of the most exciting research topics in this area, including targeting receptors such as PD-1/PD-L1, TIGIT/CD155, GITR/GITRL and more.
Please check the highlighted fields and try again.
Please enter your first and last name.
Please enter the name of the company or institution you work at.
Please enter your mailing address.
Please enter the e-mail address you would like to be contacted at.